IRADIMED CORPORATION announced its financial results for the fourth quarter ended December 31, 2023, reporting a 17.4% year-over-year revenue growth to $17.5 million. The company's net income was $4.5 million, or $0.36 per diluted share, and non-GAAP net income was $5.0 million, or $0.39 per diluted share.
Reported record revenue of $17.5 million for the fourth quarter of 2023.
GAAP diluted EPS was $0.36 and non-GAAP diluted EPS was $0.39 for the fourth quarter of 2023.
Operating income was $5.2 million, an increase of 21.3%, compared to the same period in 2022.
Initiated a quarterly dividend in 2024.
The Company expects to report revenue of $72.0 million to $74.0 million, GAAP diluted earnings per share of $1.37 to $1.47, and non-GAAP diluted earnings per share of $1.52 to $1.62 for the full-year of 2024. For the first quarter of 2024, the Company expects to report revenue of $17.0 million to $17.3 million, GAAP diluted earnings per share of $0.29 to $0.31, and non-GAAP diluted earnings per share of $0.33 to $0.35.
Analyze how earnings announcements historically affect stock price performance